The Rise Of Super Generics Market Is Driven By Cost Efficiency

By Author: colin
Total Articles: 197
Comment this article

The Super Generics market refers to the production and sale of identical copied versions of FDA approved drugs that have lost their patent protection. These generic drugs offer similar therapeutic effects to their brand name equivalents but are sold at much lower costs. Super generics are considered bioequivalent to their branded reference drugs by virtue of having same active ingredients, route of administration, dosage form and strength. They offer significant cost savings ranging from 30-80% lesser than the original branded versions.

The Super Generics Market is estimated to be valued at US$ 84 Bn in 2024 and is expected to exhibit a CAGR of 8.3% over the forecast period 2024-2031.

Super generics are fast replacing original branded drugs and capturing a major share of the off-patent market owing to their significantly lower prices. Generics account for over 90% of all dispensed prescriptions in the US currently.

Key Takeaways

Key players operating in the Super Generics market are Accord Healthcare, Alcon Laboratories, Azurity Pharmaceuticals, Baxter, and Dr. Reddy’s Laboratories. These companies ...
... are spearheading R&D activities to develop low-cost generic versions of blockbuster drugs losing patent exclusivity. Their wide product portfolios and global supply chains enable consistent supply of affordable medicines worldwide.

Growing demand for cost-effective medicines globally is a major driver for the super generics market. Developed economies are shifting to generics to control rising healthcare expenditures while developing nations lack adequate healthcare budgets. This widespread need for affordable treatment is reflected in the generics market capturing over 80% share of the pharmaceutical industry currently.

The super generics industry is also expanding rapidly through global partnerships and acquisitions. Companies are eyeing opportunities in emerging pharma hubs of Asia, Latin America, Middle East and Africa to compensate for saturation in developed markets. Regulatory approvals are also being accelerated in these regions to ensure accessibility of essential low-cost drugs.

Market Drivers

Cost efficiency is the primary growth driver for the super generics market. The development and manufacturing costs for super generics are significantly lower than innovator drugs since they do not require substantial R&D investments and clinical trials. This allows companies to price their products up to 80% lower than original branded medications. With healthcare budgets under increasing pressure worldwide, super generics offer a highly cost-effective means to attain treatment targets set by governments and global health organizations. Their rising demand is thus fueled by constant efforts from payers as well as providers to contain escalating medical costs.

Impact Of Geopolitical Situation On The Growth Of Super Generics Market:

The super generics market is witnessing changes in market dynamics due to the ongoing geopolitical conflicts between various nations. The Russia-Ukraine war has impacted the supply chains of API and other raw material procurement for many generic drug manufacturers in Europe. There is a shortage of Iodine, Neodymium, Palladium, and Nickel that are critical components used in manufacturing radiographic contrast agents, MRI contrast agents, various drugs, and medical devices. This shortage is putting upward pressure on input costs. Moreover, trade sanctions on Russia have disrupted logistics and transportation networks for drug shipments originating from or transiting via Russia. Manufacturers need to optimize procurement channels and find new reliable suppliers from alternative geographic locations to deal with such geopolitical uncertainties and ensure uninterrupted supplies. The ongoing geopolitical conflicts could potentially divert investments to other emerging markets with more stable political and economic conditions. This risk warrants strategic portfolio diversification by pharma companies into multiple growing markets to mitigate regional overdependence.

The super generics market in terms of value is currently concentrated highly in North America and Western Europe due to their well-established healthcare infrastructure and reimbursement mechanisms. However, Asia Pacific region, led by China and India, offers highly promising growth opportunities for super generic drugs over the forecast period. This is attributed to rising health awareness, growing geriatric population susceptible to chronic diseases, increasing healthcare expenditures, and governments pushing for more affordable generic alternatives to reduce treatment costs. The super generics market is estimated to witness the fastest growth in the Asia Pacific region during 2024-2031 on account of its large patient pool and improving access to medicines resulting from various initiatives by public and private healthcare organizations.

Geographical Regions With Concentration In Super Generics Market:

The super generics market in terms of value is currently concentrated highly in North America and Western Europe due to their well-established healthcare infrastructure and reimbursement mechanisms. The United States holds the largest share under the North American regional market owing to the presence of a developed generic drugs sector and rising healthcare spending on prescription drugs. Furthermore, countries like Germany, France, and the UK dominate the European super generics marketspace attributable to their growing geriatric population and availability of favorable national policies supporting biosimilars uptake.

Fastest Growing Region In Super Generics Market:

However, Asia Pacific region, led by China and India, offers highly promising growth opportunities for super generic drugs over the forecast period. This is attributed to rising health awareness, growing geriatric population susceptible to chronic diseases, increasing healthcare expenditures, and governments pushing for more affordable generic alternatives to reduce treatment costs. The super generics market is estimated to witness the fastest growth in the Asia Pacific region during 2024-2031 on account of its large patient pool and improving access to medicines resulting from various initiatives by public and private healthcare organizations.

Get more insights on this topic: https://www.timessquarereporter.com/news/the-rising-super-generics-market-driven-by-increased-accessibility-of-affordable-medicines

Author Bio:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )

What Are The Key Data Covered In This Super Generics Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Super Generics Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Super Generics Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Super Generics Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Super Generics Market vendors

FAQ’s

Q.1 What are the main factors influencing the Super Generics Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Super Generics Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Super Generics Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it